Medtronic plc (BVMF:MDTC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 536.57B -7.9% |
| Revenue (ttm) | 182.20B +8.4% |
| Net Income | 24.05B +3.0% |
| EPS | 18.69 +3.3% |
| Shares Out | n/a |
| PE Ratio | 22.31 |
| Forward PE | 13.55 |
| Dividend | 5.09 (2.42%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 20 |
| Open | 211.05 |
| Previous Close | n/a |
| Day's Range | 210.63 - 211.47 |
| 52-Week Range | 183.88 - 277.20 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 3, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Medtronic price target lowered to $83 from $84 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Medtronic (MDT) to $83 from $84 and keeps a Neutral rating on the shares. The company’s Q4 results carried…
Medtronic price target lowered to $97 from $112 at Bernstein
Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $97 from $112 and keeps an Outperform rating on the shares following a solid Q4. After weaker…
Medtronic price target lowered to $86 from $95 at Truist
Truist lowered the firm’s price target on Medtronic (MDT) to $86 from $95 and keeps a Hold rating on the shares. The company delivered a Q4 organic revenue beat but…
Medtronic price target lowered to $85 from $93 at Baird
Baird analyst David Rescott lowered the firm’s price target on Medtronic (MDT) to $85 from $93 and keeps a Neutral rating on the shares. The firm updated its model following…
Medtronic price target lowered to $85 from $90 at UBS
UBS analyst Priya Sachdeva lowered the firm’s price target on Medtronic (MDT) to $85 from $90 and keeps a Neutral rating on the shares. Medtronic’s solid Q4 results and seemingly…
Medtronic management to meet with Piper Sandler
Meeting to be held in Los Angeles on June 10-11 hosted by Piper Sandler.
Medtronic upgraded to Buy at BTIG on consistent organic growth
BTIG upgraded Medtronic (MDT) to Buy from Neutral with a $90 price target Medtronic has demonstrated consistent mid-single digit organic growth the past several quarters and the trajectory is improvin...
Medtronic upgraded to Buy from Neutral at BTIG
BTIG upgraded Medtronic (MDT) to Buy from Neutral.
Medtronic price target lowered to $80 from $95 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Medtronic (MDT) to $80 from $95 and keeps a Hold rating on the shares. Medtronic’s Affera pulsed-field-ablation technology continues to…
Medtronic price target lowered to $101 from $120 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Medtronic (MDT) to $101 from $120 and keeps a Buy rating on the shares. The company’s Q4 revenue and EPS…
Medtronic sees Q1 EPS $1.38-$1.40, consensus $1.39
Says with robotics penetration still in high-single digits, sees significant runway ahead. Says expects foreign exchange to be neutral to roughly $100M headwind in FY27. Says expects FY27 tariff impac...
Morning Movers: Macy’s and Medtronic rise after quarterly reports
Stock futures are slightly lower while investors digest stronger-than-expected employment data and wait for Friday’s official nonfarm payrolls report. According to ADP, private-sector employers added ...
Medtronic announces investments in two intracardiac echocardiography companies
Medtronic (MDT) announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography, or ICE, catheter technologies. ICE catheters provide real-t...
Medtronic Earnings Call Transcript: Q4 2026
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across key segments and significant progress in innovation and portfolio focus. FY27 guidance anticipates continued top-line acceleration, margin leverage, and ongoing investment despite tariff and macro headwinds.
Medtronic Earnings release: Q4 2026
Medtronic released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
Medtronic Slides: Q4 2026
Medtronic has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
Medtronic (MDT) announced significant milestones to unlock expanded indications for the Hugo robotic-assisted surgery system in the United States and to shape the future of surgery. General surgery in...
Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts' estimates.
Medtronic Posts Higher Profit, Sales
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assis...
Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of techno...
Medtronic beats quarterly estimates on robust demand for heart devices
Medtronic beat Wall Street estimates for fourth-quarter revenue and adjusted profit on Wednesday, riding the wave of steady demand for its heart devices used in complex cardiac procedures.
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
GALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (F...
7 Dividend Stocks to Beat Inflation
Historically, energy stocks have performed the best when inflation spikes.